• ̍̍ CSE: BRAX
  • ̍̍ OTC: BRAXF
  • ̍̍ FWB: 4960

DISCOVERY

July 7, 2021

EXPERIMENTAL MEDICINE IN PSYCHIATRY

BRAXIA SCIENTIFIC TO DISCUSS PSYCHIATRIC TREATMENT DISCOVERY AND DEVELOPMENT WITH OXFORD UNIVERSITY RESEARCHERS AT AIMDAY EXPERIMENTAL MEDICINE IN PSYCHIATRY ON JULY 7, 2021 TORONTO, ONTARIO July 7, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research and development company along with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the upcoming Academic Industry Meeting Day (AIMday) on “Experimental Medicine in Psychiatry,” hosted by Oxford University on Wednesday, July 7, 2021. Braxia CEO Dr. Roger McIntyre will engage with Oxford scientists on the question of “How can we advance treatment discovery and development in psychiatry targeting cognition?” They will describe how research will be conducted with ketamine and psychedelics that integrates machine-learning, proof-of-mechanism research and implementation science which will be critical for the...